Walleye Capital’s Trillium Therapeutics Inc. TRIL Stock Holding History

Walleye Capital’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-70,252	Closed	-$1.23K	–	2528
2021 Q3	$1.23K	Buy	+70,252	New	+$821K	0.04%	359

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Walleye Capital's TRIL Position: Q4 2021 in Review

Walleye Capital sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 70,252 shares — an estimated $1.23K sold.

Walleye Capital first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $1.23K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Walleye Capital reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Walleye Capital sold 70,252 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.23K.
Walleye Capital first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Walleye Capital's Trillium Therapeutics Inc. position peaked at $1.23K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Walleye Capital's 13F filing for Q4 2021, filed 3 Mar 2022.